Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA (ecstasy): An 18F-dopa PET Study

Neuropsychopharmacology

Volumn 36, Issue 4, 2011, Pages 735-743

  Tai, Yen F ^a   Hoshi, Rosa ^b   Brignell, Catherine M ^c   Cohen, Lisa ^a,b   Brooks, David J ^a,d   Curran, H Valerie ^b   Piccini, Paola ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^d GE HEALTHCARE   (United Kingdom)

Author keywords

addiction; dopamine; ecstasy; F dopa; MDMA; PET

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CARBIDOPA; DOPAMINE; ENTACAPONE; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DRUG EFFECT; HAIR ANALYSIS; HUMAN; MALE; MULTIPLE DRUG ABUSE; NIGRONEOSTRIATAL SYSTEM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; URINALYSIS;

ADULT; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; DOPAMINE; HUMANS; MALE; MIDDLE AGED; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; POSITRON-EMISSION TOMOGRAPHY; SUBSTANCE-RELATED DISORDERS; SUBSTANTIA NIGRA; TIME FACTORS;

EID: 79951516836     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2010.201     Document Type: Article

References (56)

1. Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K et al (2007). Substance use in a population-based clinic sample of people with first-episode psychosis. Br J Psychiatry 190: 515-520. (Pubitemid 46868836)
2. Barratt E, Patton JH (1983). Impulsivity: cognitive, behavioural and psychophysiological correlates. In: Zuckerman M (ed). Biological Basis of Sensation Feeling, Impulsivity and Anxiety. Erlbaum: Hillsdale, NJ.
3. Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M et al (2006). Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Arch Gen Psychiatry 63: 1386-1395. (Pubitemid 44878522)
4. Brooks DJ (2003). Imaging end points for monitoring neuroprotection in Parkinson's disease. Ann Neurol 53: S110-S118.
5. Buschke H, Fuld PA (1974). Evaluating storage, retention, and retrieval in disordered memory and learning. Neurology 24: 1019-1025.
6. Buss AH, Perry M (1992). The aggression questionnaire. J Pers Soc Psychol 63: 452-459.
7. Colado MI, O'Shea E, Green AR (2004). Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function. Psychopharmacology (Berl) 173: 249-263. (Pubitemid 38703798)
8. Commins DL, Vosmer G, Virus RM, Woolverton WL, Schuster CR, Seiden LS (1987). Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain. J Pharmacol Exp Ther 241: 338-345. (Pubitemid 17119380)
9. Cowan RL (2007). Neuroimaging research in human MDMA users: a review. Psychopharmacology (Berl) 189: 539-556. (Pubitemid 44791223)
10. de Win MM, Jager G, Booij J, Reneman L, Schilt T, Lavini C et al (2008). Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 131: 2936-2945.
11. Egerton A, Demjaha A, McGuire P, Mehta MA, Howes OD (2010). The test-retest reliability of 18F-DOPA PET in assessing striatal and extrastriatal presynaptic dopaminergic function. Neuro-Image 50: 524-531.
12. EMCDDA (2005). Annual Report 2005: The State of the Drugs Problem in Europe. EMCDDA: Luxembourg.
13. First MB, Spitzer RL, Gibbon M, Williams JB (1997). Structured Clinical Interview for DSM-IV Axis I Disorders. American Psychiatric Publishing: Washington, DC.
14. Gerra G, Zaimovic A, Moi G, Giusti F, Gardini S, Delsignore R et al (2002). Effects of (+/-) 3,4-methylene-dioxymethamphetamine (ecstasy) on dopamine system function in humans. Behav Brain Res 134: 403-410. (Pubitemid 34912719)
15. Gibson H (1977). Manual of the Gibson Spiral Maze. Hodder: London.
16. Gouzoulis-Mayfrank E, Daumann J (2006). The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol 20: 188-193.
17. Green AR, Mechan AO, Elliott JM, O'Shea E, Colado MI (2003). The pharmacology and clinical pharmacology of 3,4-methylene-dioxymethamphetamine (MDMA, 'ecstasy'). Pharmacol Rev 55: 463-508. (Pubitemid 37013213)
18. Hayman MAX (1942). Two minute clinical test for measurement of intellectual impairment in psychiatric disorders. Arch Neurol Psychiatry 47: 454-464.
19. Hietala J, Syvalahti E, Vuorio K, Rakkolainen V, Bergman J, Haaparanta M. et al (1995). Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 346: 1130-1131.
20. Hoshi R, Mullins K, Boundy C, Brignell C, Piccini P, Curran HV (2007). Neurocognitive function in current and ex-users of ecstasy in comparison to both matched polydrug-using controls and drug-naive controls. Psychopharmacology (Berl) 194: 371-379. (Pubitemid 47389342)
21. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Grasby PM, McGuire PK (2007). Molecular imaging studies of the striatal dopaminergic system in psychosis and predictions for the prodromal phase of psychosis. Br J Psychiatry Suppl 51: s13-s18. (Pubitemid 350273183)
22. Howes OD, Montgomery AJ, Asselin MC, Murray RM, Valli I, Tabraham P. et al (2009). Elevated striatal dopamine function linked to prodromal signs of schizophrenia. Arch Gen Psychiatry 66: 13-20.
23. Kish SJ, Furukawa Y, Ang L, Vorce SP, Kalasinsky KS (2000). Striatal serotonin is depleted in brain of a human MDMA (ecstasy) user. Neurology 55: 294-296. (Pubitemid 30604635)
24. Kuniyoshi SM, Jankovic J (2003). MDMA and parkinsonism. N Engl J Med 349: 96-97.
25. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R et al (2006). Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59: 459-466. (Pubitemid 43358066)
26. Logan BJ, Laverty R, Sanderson WD, Yee YB (1988). Differences between rats and mice in MDMA (methylenedioxymethylam-phetamine) neurotoxicity. Eur J Pharmacol 152: 227-234.
27. Maas JW, Bowden CL, Miller AL, Javors MA, Funderburg LG, Berman N et al (1997). Schizophrenia, psychosis, and cerebral spinal fluid homovanillic acid concentrations. Schizophr Bull 23: 147-154. (Pubitemid 27087914)
28. Mason O, Linney Y, Claridge G (2005). Short scales for measuring schizotypy. Schizophr Res 78: 293-296. (Pubitemid 41254030)
29. McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT et al (2008). Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ('ecstasy') users: relationship to cognitive performance. Psychopharmacology (Berl) 200: 439-450.
30. McGuire PK, Cope H, Fahy TA (1994). Diversity of psychopathol-ogy associated with use of 3,4-methylenedioxymethampheta-mine ('ecstasy'). Br J Psychiatry 165: 391-395. (Pubitemid 24274162)
31. Melega WP, Raleigh MJ, Stout DB, Huang SC, Phelps ME (1997). Ethological and 6-[18F]fluoro-L-DOPA-PET profiles of long-term vulnerability to chronic amphetamine. Behav Brain Res 84: 259-268. (Pubitemid 27112702)
32. Mesulam MM (1985). Principles of Behavioral Neurology. F.A. Davis: Philadelphia, PA.
33. Mintzer S, Hickenbottom S, Gilman S (1999). Parkinsonism after taking ecstasy. N Engl J Med 340: 1443.
34. Montgomery AJ, Thielemans K, Mehta MA, Turkheimer F, Mustafovic S, Grasby PM (2006). Correction of head movement on PET studies: comparison of methods. J Nucl Med 47: 1936-1944. (Pubitemid 47544981)
35. Montoya AG, Sorrentino R, Lukas SE, Price BH (2002). Long-term neuropsychiatric consequences of 'ecstasy' (MDMA): a review. Harv Rev Psychiatry 10: 212-220. (Pubitemid 34791184)
36. Nash JF, Meltzer HY, Gudelsky GA (1990). Effect of 3,4-methyl- enedioxymethamphetamine on 3,4-dihydroxyphenylalanine accumulation in the striatum and nucleus accumbens. J Neurochem 54: 1062-1067.
37. Nikolaus S, Antke C, Muller HW (2009). In vivo imaging of synaptic function in the central nervous system: II. Mental and affective disorders. Behav Brain Res 204: 32-66.
38. Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW (1990). Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 28: 1021-1034. (Pubitemid 20347464)
39. Owen AM, Sahakian BJ, Semple J, Polkey CE, Robbins TW (1995). Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 33: 1-24.
40. Patlak CS, Blasberg RG (1985). Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab 5: 584-590. (Pubitemid 16218234)
41. Pickar D, Labarca R, Doran AR, Wolkowitz OM, Roy A, Breier A et al (1986). Longitudinal measurement of plasma homovanillic acid levels in schizophrenic patients. Correlation with psychosis and response to neuroleptic treatment. Arch Gen Psychiatry 43: 669-676. (Pubitemid 16094179)
42. Pragst F, Balikova MA (2006). State of the art in hair analysis for detection of drug and alcohol abuse. Clin Chim Acta 370: 17-49. (Pubitemid 44137285)
43. Ramirez-Bermudez J, Ruiz-Chow A, Perez-Neri I, Soto-Hernandez JL, Flores-Hernandez R, Nente F et al (2008). Cerebrospinal fluid homovanillic acid is correlated to psychotic features in neurological patients with delirium. Gen Hosp Psychiatry 30: 337-343. (Pubitemid 351862311)
44. Reitan RM (1959). A Manual for the Administration and Scoring of the Trail Making Test. Indiana University Press: Indianapolis, USA.
45. Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB et al (2001). Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons. Lancet 358: 1864-1869. (Pubitemid 34008653)
46. Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma JB, Gunning B et al (2002). Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study-preliminary report. Psychopharmacology (Berl) 159: 335-340. (Pubitemid 34143383)
47. Reneman L, de Win MM, van den Brink W, Booij J, den Heeten GJ Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J Psychopharmacol, (2006) 20: 164-175.
48. Selvaraj S, Hoshi R, Bhagwagar Z, Murthy NV, Hinz R, Cowen P. et al (2009). Brain serotonin transporter binding in former users of MDMA ('ecstasy'). Br J Psychiatry 194: 355-359.
49. Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC (1999). Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br J Psychiatry 175: 63-69. (Pubitemid 29307857)
50. Turkheimer FE, Brett M, Visvikis D, Cunningham VJ (1999). Multiresolution analysis of emission tomography images in the wavelet domain. J Cereb Blood Flow Metab 19: 1189-1208. (Pubitemid 30176447)
51. Wesnes K, Warburton DM (1983). Effects of smoking on rapid information processing performance. Neuropsychobiology 9: 223-229. (Pubitemid 13018097)
52. Whone AL, Bailey DL, Remy P, Pavese N, Brooks DJ (2004). A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study. J Nucl Med 45: 1135-1145. (Pubitemid 47611658)
53. Wilson B, Cockburn J, Baddeley A (1985). The Rivermead Behavioural Memory Test. Thames Valley Text: Reading, UK.
54. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM et al (1996). Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2: 699-703. (Pubitemid 26191961)
55. Winstock AR (1991). Chronic paranoid psychosis after misuse of MDMA. BMJ 302: 1150-1151.
56. Yuan J, Cord BJ, McCann UD, Callahan BT, Ricaurte GA (2002). Effect of depleting vesicular and cytoplasmic dopamine on methylenedioxymethamphetamine neurotoxicity. J Neurochem 80: 960-969. (Pubitemid 34809948)